Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2020-09-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from gene-modified cancer cells may help the body build an effective
immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with
imatinib mesylate may be an effective treatment for chronic myelogenous leukemia.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy
when given together with imatinib mesylate in treating patients with chronic phase chronic
myelogenous leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center National Cancer Institute (NCI)